Chart of trial progress
CENTAUR trial timeline (click to enlarge)

The CENTAUR trial, a phase 2 clinical trial of AMX0035 for ALS, enrolled its first patient in July of 2017 and reached its primary clinical endpoint in late 2019, when patients were given the option of moving to an open-label extension to study long-term use of the drug.

News about the study includes:

Initial Trial Results Publication

On September 2, 2020 the New England Journal of Medicine published the results of the unique trial, showing significant slowing of ALS disease progression. This is the first time an ALS therapy has shown effectiveness in accomplishing more than a reduction of symptoms, opening the door to preventing nerve cell death and offering hope to individuals with ALS and their families.

Hear from the Director of the Sean M. Healey and AMG Center for ALS Merit Cudkowicz, MD, MSc and CENTAUR Trial Lead Investigator Sabrina Paganoni, MD, PhD, as they share details of the trial results and next steps in the treatment process.

Read full announcement


Mass General researchers shared information about the trial in a webinar hosted the Northeast ALS Consortium (NEALS) on Sept. 4, 2020. A recording is available at